Ignite Creation Date:
2025-12-25 @ 12:43 AM
Ignite Modification Date:
2025-12-25 @ 10:55 PM
Study NCT ID:
NCT04758767
Status:
COMPLETED
Last Update Posted:
2025-04-03
First Post:
2021-02-08
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
CID-103 (Anti-CD38 Antibody) in Previously Treated Relapsed or Refractory Multiple Myeloma
Sponsor:
CASI Pharmaceuticals, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-03-22
Start Date Type:
ACTUAL
Primary Completion Date:
2023-01-19
Primary Completion Date Type:
ACTUAL
Completion Date:
2023-01-19
Completion Date Type:
ACTUAL
First Submit Date:
2021-02-08
First Submit QC Date:
None
Study First Post Date:
2021-02-17
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-04-01
Last Update Post Date:
2025-04-03
Last Update Post Date Type:
ACTUAL